Real-World Perspectives in Managing CLL Treatment

Jointly provided by


Support for this activity has been provided through educational grants from AbbVie Inc. and AstraZeneca Pharmaceuticals.

Release date: 5/18/2023

Expiration date:  5/18/2024

Estimated time to complete: 0.75 hours


Management options for chronic lymphocytic leukemia (CLL) have expanded in recent years. The emergence of new immunotherapeutic and targeted agents for both the first-line and relapsed/refractory settings—though of course beneficial for CLL patients—represents a challenge to clinicians, who must navigate the indicated uses, mechanisms of action, and toxicity profiles of these new agents. In determining optimal treatment plans, clinicians are also confronted with significant advances in the use of cytogenetic and molecular tests to stratify risk and determine prognosis.

This interactive activity presents the points of view of doctors and patients on issues relating to current challenges in CLL care. Each point of view is followed by a brief discussion that will help oncologists and hematologist-oncologists select the most appropriate targeted therapies, taking into account patient genetics, treatment adverse events, and previous treatments.


Lindsey E. Roeker, MD, MSCE—Program Chair
Assistant Attending L1
Memorial Sloan Kettering Cancer Center
New York, New York

Michael Choi, MD
Associate Clinical Professor
University of California, San Diego School of Medicine
La Jolla, California

Geoffrey Grubbs—Patient advocate
Washington, DC

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, hematologist-oncologists, and other clinicians who care for patients with CLL.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Interpret the cytogenetic, molecular, and other standard staging tests used to define risk and prognosis for patients with CLL
  • Distinguish between the indicated uses, mechanisms of action, and safety of current and emerging immunotherapeutic and targeted agents for patients with CLL
  • Outline a treatment plan to achieve the deepest and most durable response while balancing the risk for toxicities in previously untreated CLL patients and patients with relapsed/refractory CLL
  • Evaluate emerging prospective and real-world data on novel treatment sequencing strategies for managing relapsed/refractory CLL and its potential implications on clinical practice

Accreditation and Credit Designation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy, the Lymphoma Research Foundation, and RedMedEd. Purdue University College of Pharmacy is accredited by the ACCME to provide continuing medical education for physicians.

Purdue University College of Pharmacy designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships occurring in the past 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity.

All of the relevant financial relationships listed for these individuals have been mitigated. Relationship information appears below:

Michael Choi, MD, has disclosed the following relevant financial relationships:
Advisory board: AbbVie, Genentech
Research funding: AbbVie, Geron, Beigene, Protagonist
Speaker: OncLive

Lindsey Roeker, MD, MSCE, has disclosed the following relevant financial relationships:
Consultant: AbbVie, Ascentage, AstraZeneca, BeiGene, Janssen, Loxo Oncology, Pharmacyclics, Pfizer, TG Therapeutics
Research funding: Abbott Laboratories, Loxo Oncology
Stock ownership: Abbott Laboratories

Geoffrey Grubbs has disclosed no relevant financial relationships.

Lymphoma Research Foundation
The planners have disclosed no relevant financial relationships.

Purdue University
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

The planners have disclosed no relevant financial relationships.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Purdue University College of Pharmacy, RedMedEd, Lymphoma Research Foundation, AbbVie, and AstraZeneca do not recommend the use of any agent outside the labeled indications.


The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Purdue University College of Pharmacy, RedMedEd, Lymphoma Research Foundation, AbbVie, or AstraZeneca. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the program evaluation. Certificates can be printed immediately.

Contact Information

For questions regarding CME credit, contact Purdue University College of Pharmacy at
For technical questions related to this activity, please contact RedMedEd at 610.251.6841 or

Hardware/Software Requirements

  • iPad, iPad Mini (iPadOS 15 or higher), iPhone (iOS 15 or higher), or Android device (OS 11 or higher) with an Internet connection
    • Internet browsers: Chrome, Firefox, Safari
  • A computer with an Internet connection
    • Internet browsers (PC): Chrome, Firefox, Microsoft Edge
    • Internet browsers (Mac): Chrome, Firefox, Safari


This website is managed by RedMedEd, and RedMedEd’s printed privacy policy applies to this site. CME credit for this activity is provided by Purdue University College of Pharmacy. If you register for CME credit for this educational activity, RedMedEd will forward relevant personally identifiable information to Purdue University College of Pharmacy so that records can be maintained concerning any credits issued to you. Aggregated data concerning registrations, posttests, and evaluations may be shared, but RedMedEd will not knowingly share any personally identifiable information. The information you provide on this site may be used to contact you about your CME credit or other relevant educational activities provided through Purdue University College of Pharmacy or RedMedEd. For more information, contact Purdue University College of Pharmacy at or

Purdue University College of Pharmacy’s Office of Continuing Education follows the existing privacy policy issued by Purdue University, amended for applicability related to continuing education.

Collection and Use of Information

Personal information (such as name, address, or telephone number) is collected and used only to ensure appropriate continuing education credit is issued to the learner and to inform the learner about additional products or services that may be of interest. Purdue does not sell, trade, or rent personal information to others outside of our own entity.


© 2023. This CME/CE-certified program is held as copyrighted by Purdue University College of Pharmacy, RedMedEd, and the Lymphoma Research Foundation. Through this notice, Purdue University College of Pharmacy, RedMedEd, and the Lymphoma Research Foundation grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.